Abstract
Abstract
Background
The underlying pathophysiology of Parkinson's disease is complex, involving different molecular pathways, including brain iron deposition and mitochondrial dysfunction. At a molecular level, these disease mechanisms are likely interconnected. Therefore, they offer potential strategies for disease-modifying treatments. We aimed to investigate subcortical brain iron deposition as a potential predictor of the bioenergetic status in patients with idiopathic Parkinson’s disease.
Methods
Thirty patients with idiopathic Parkinson's disease underwent multimodal MR imaging (T1, susceptibility-weighted imaging, SWI) and 31phosphorus magnetic resonance spectroscopy imaging. SWI contrast-to-noise ratios served as a measure for brain iron deposition in the putamen, caudate, globus pallidus, and thalamus and were used in a multiple linear regression model to predict in-vivo energy metabolite ratios.
Results
Subcortical brain iron deposition, particularly in the putamen and globus pallidus, was highly predictive of the region-specific amount of high-energy-containing phosphorus metabolites in our subjects.
Conclusions
Our study suggests that brain iron deposition but not the variability of individual volumetric measurements are highly predictive of mitochondrial impairment in vivo. These findings offer the opportunity, e.g., by using chelating therapies, to improve mitochondrial bioenergetics in patients with idiopathic Parkinson's disease.
Funder
Parkinson's Disease Foundation
Deutsche Gesellschaft für Parkinson und Bewegungsstörungen
Deutsche Forschungsgemeinschaft
Else Kröner-Fresenius-Stiftung
Bundesministerium für Bildung und Forschung
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine
Reference45 articles.
1. Anderson TW, Darling DA. Asymptotic theory of certain “goodness of fit” criteria based on stochastic processes. Ann Math Statist. 1952;23:193–212.
2. Andersson JLR, Jenkinson M, Smith S. Non-linear registration aka spatial normalisation. FMRIB Technical Report TRO7JA2 2007.
3. Barbosa JHO, Santos AC, Tumas V, et al. Quantifying brain iron deposition in patients with Parkinson’s disease using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging. 2015;33:559–65.
4. Chan S, Lian Q, Chen MP, et al. Deferiprone inhibits iron overload-induced tissue factor bearing endothelial microparticle generation by inhibition oxidative stress induced mitochondrial injury, and apoptosis. Toxicol Appl Pharmacol. 2018;338:148–58.
5. D’Agostino RB, Belanger A, D’Agostino RB. A suggestion for using powerful and informative tests of normality. Am Stat. 1990;44:316–21.